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Abstract: The endothelium can evoke relaxations (dilatations) of the underlying vascular 
smooth muscle, by releasing vasodilator substances. The best characterized endothelium-
derived relaxing factor (EDRF) is nitric oxide (NO), which is synthesized by the 
endothelial isoform of nitric oxide synthase (eNOS).  Endothelium-dependent relaxations 
involve both pertussis toxin-sensitive Gi (e.g. responses to serotonin, sphingosine 1-
phosphate, alpha2-adrenergic agonists and thrombin) and pertussis toxin-insensitive Gq 
(e.g. adenosine diphosphate and bradykinin) coupling proteins.  eNOS undergoes a 
complex pattern of intracellular regulation, including post-translational modifications 
involving enzyme acylation and phosphorylation.  eNOS is reversibly targeted to signal-
transducing plasmalemmal caveolae where the enzyme interacts with a number of 
regulatory proteins, many of which are modified in cardiovascular disease states.  The 
release of NO by the endothelial cell can be up- (e.g. by estrogens, exercise and dietary 
factors) and down-regulated (e.g. oxidative stress, smoking and oxidized low-density 
lipoproteins [oxyLDL]). It is reduced in the course of vascular disease (e.g. diabetes and 
hypertension). Arteries covered with regenerated endothelium (e.g. following angioplasty) 
selectively lose the pertussis-toxin sensitive pathway for NO-release which favors 
vasospasm, thrombosis, penetration of macrophages, cellular growth and the inflammatory 
reaction leading to atherosclerosis.  The unraveling of the complex interaction of the 
pathways regulating the presence and the activity of eNOS will enhance the understanding 
of the perturbations in endothelium-dependent signaling that are seen in cardiovascular 
disease states, and may lead to the identification of novel targets for therapeutic 
intervention.  
Short Title: NO and Endothelial Dysfunction 
Keywords: diabetes, G-proteins, hypertension, nitric oxide  
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1. Introduction 
Robert Furchgott demonstrated that the removal of the endothelial layer from isolated arteries 
prevents the in vitro dilator response to acetylcholine [Furchgott & Zawadzki, 1980]. Early 
bioassay studies demonstrated that the endothelial cells cause arterial relaxation by releasing a 
vasoactive substance(s) which was termed endothelium-derived relaxing factor (EDRF) 
[Furchgott & Zawadzki, 1980; Rubanyi et al., 1985]. The original EDRF [Furchgott & 
Zawadzki, 1980] stimulates soluble guanylyl cyclase in the vascular smooth muscle cells and 
thus increases the production of cyclic guanosine monophosphate (cyclic GMP) [see Furchgott & 
Vanhoutte, 1989; Lüscher & Vanhoutte 1990; Vanhoutte et al., 2009]. It is rapidly destroyed by 
superoxide anions [Rubanyi et al., 1986]. These experimental facts led to the proposal and the 
demonstration that EDRF is nitric oxide (NO) [see Vanhoutte, 2009].   Besides NO, a number of 
endothelium-derived factors (EDHFs) and the opening of gap junctions can cause NO-
independent hyperpolarizations of the   underlying vascular smooth muscle and thus 
endothelium-dependent relaxations [see Busse et al., 2002; Feletou & Vanhoutte 2006a, 2009]. 
When the ability of the endothelial cells to release NO [and to cause endothelium-dependent 
hyperpolarizations] is reduced, this appears to be the first step in the chain of events that leads to 
atherosclerosis and coronary disease [see Vanhoutte et al., 2009].  Thus, endothelial dysfunction 
has become a hallmark and a predictor of cardiovascular disease. This article focuses on the 
cellular mechanisms leading to the release of endothelium-derived nitric oxide [EDNO] and how 
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reduction in such release plays a key role role in the genesis of vascular disease. For the survey 
of the original experimental literature, the reader will be referred mainly to more exhaustive 
previous review articles.  
 
2. Nitric Oxide Protector of the vascular wall  
As such, endothelium-dependent relaxations to acetylcholine are mainly of pharmacological 
interest since few blood vessels are innervated by cholinergic nerves. However, a number of 
more physiological stimuli [physical forces, circulating hormones (catecholamines, vasopressin, 
aldosterone), plasma constituents (thrombin, sphingosine 1-phosphate), platelet products 
(serotonin, adenosine diphosphate), and autacoids (histamine, bradykinin, prostaglandin E4)] 
share with acetylcholine the ability to evoke the release of EDNO (Figure 1) [see Lüscher & 
Vanhoutte, 1990; Vanhoutte et al., 2009]. NO plays a key role in the protection exerted by the 
endothelium against coronary disease. It is produced by the endothelial constitutive isoform of 
NO synthase (eNOS, NOS III) (Figure 2) [see Moncada, 1997;  Dudzinksi et  al., 2006; 
Dudzinski and Michel, 2007; Vanhoutte et al., 2009]. NO not only prevents abnormal 
constriction (vasospasm) of the coronary arteries, which favors intraluminal clot formation, but 
also inhibits the aggregation of platelets, the expression of adhesion molecules at the surface of 
the endothelial cells, and hence the adhesion and penetration of white blood cells (macrophages), 
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and the release and action of the vasoconstrictor and mitogenic peptide endothelin-1 (Figure 3). 
The protective release of NO is triggered by the local presence of thrombin and substances 
released by aggregating platelets.  When this protective role of NO is curtailed, the inflammatory 
response that leads to atherosclerosis is initiated [see Vanhoutte et al., 2009].  
The role played by the endothelial cells to protect against thrombin and platelet products by 
increasing the activity of eNOS has been demonstrated both in vitro and in vivo [see Harrison 
2001; Vanhoutte et al., 2009].  Serotonin (5-hydroxytryptamine, 5HT) and adenosine 
diphosphate (ADP) are the two mediators released by aggregating platelets that can activate 
eNOS and thus augment the production of NO. Serotonin is the most important and stimulates 5-
HT1D serotonergic receptors of the endothelial cell membrane. ADP is a relatively minor 
contributor of the response to platelets and acts on P2y purinoceptors (Figure 3). The serotonergic 
receptors and those for thrombin are coupled to the activation of eNOS through pertussis toxin-
sensitive Gi-proteins, while the P2y-purinoceptors are linked to the enzyme by Gq- proteins [see 
Vanhoutte et al., 2009].If the endothelium is absent or dysfunctional such relaxations are no 
longer observed, and aggregating platelets induce constrictions (vasospasm), because they 
release the powerful vasoconstrictors thromboxane A2 and serotonin.  
The physiological importance of the endothelium-dependent relaxations to platelet products is 
obvious [see Feletou & Vanhoutte, 2006b; Vanhoutte et al., 2009]. Thus, if platelet aggregation 
occurs in a coronary artery with a healthy endothelium the release by the platelets of serotonin 
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(and ADP) and the local production of thrombin will stimulate the endothelial cells with the 
resulting release of NO. The endothelial mediator will cause the underlying smooth muscle to 
relax, thus increasing blood flow and mechanically impeding the progression of the coagulation 
process. NO also exerts in synergy with prostacyclin an immediate feed-back inhibition on the 
platelets. When the endothelial barrier is interrupted by injury, the aggregating platelets can 
approach the vascular smooth muscle cells, and cause their contraction by releasing thromboxane 
A2   and serotonin, initiating the vascular phase of hemostasis. The endothelium-dependent 
response to aggregating platelets is not present to the same extent in all arteries, but is the most 
prominent in the coronary and cerebral circulations [see Vanhoutte et al., 2009].  
3. Intracellular regulation of endothelial nitric oxide synthase 
3.1 Enzymatic function of eNOS 
Endothelial nitric oxide synthase (eNOS) is a member of a family of three mammalian nitric 
oxide synthase (“NOS”) isoforms that catalyze the oxidation of the terminal guanidino group of 
L-arginine to produce NO and L-citrulline (see reviews in Forstermann et al 1998; Shaul and 
Anderson 2004; Dudzinski et al., 2006).  The three archetypal mammalian NOS isoforms are a] 
nNOS (NOS I) or neuronal NOS; b] iNOS (NOS II), an inducible NOS isoform expressed in a 
variety of activated tissues; and c] eNOS (NOS III) or endothelial NOS.  They are the products 
of distinct genes, and share approximately 50-60% sequence identity. Although these isoforms 
possess similar overall enzymatic and chemical properties, they contain distinctive catalytic and 
regulatory properties which characterize them. Nitric oxide synthases are bifunctional enzymes:  
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the N-terminus exhibits homology principally to the other NOS isoforms, while the C-terminal 
domain has significant sequence homology to cytochrome P450 reductases.  The NOS N-
terminus binds tetrahydrobiopterin (BH4) and heme. L-arginine binds in the enzyme active site 
near heme, while molecular oxygen is directed to the ferrous heme iron.  The binding sites for 
tetrahydrobiopterin and heme are localized along the interface of the monooxygenase domains of 
the dimeric, active form of NOS.  Binding of heme and tetrahydrobiopterin, especially for iNOS, 
may be crucial in promoting dimerization and NOS catalytic activity.  The C-terminal domain 
binds NADPH, FAD, and FMN cofactors [Steuhr, 1997].  The N- and C-terminal domains are 
linked by a short sequence that binds calmodulin, an allosteric effector that is essential for full 
NOS activity.  The intact NOS functions as a mixed function monooxygenase / reductase 
enzyme, and has the capability to synthesize a number of molecules besides NO, most notably 
superoxide anions. In all NOS catalysis reactions, electrons are shuttled within the reductase 
domain sequentially from NADPH, to FAD, and finally to FMN.  Calmodulin is believed to 
function in facilitating the flow of electrons from both the reductase domain to the 
monooxygenase domain as well as from FAD to FMN. Because electrons appear to flow from 
the reductase domain of one NOS monomer to the oxygenase domain of another NOS monomer, 
enzyme dimerization is required for full enzymatic activity (Forsterman et al 1998; Balligand 
and Feron 2009).  
3.2 Post-Translational Modifications of the eNOS Protein 
Endothelial eNOS undergoes a complex pattern of post-translational regulatory modifications 
that underly the dynamic regulation of enzymatic activity in response to physiological stimuli 
and pathophysiological conditions [See reviews in Fulton et al. 2001; Dudzinski et al. 2006; 
Sessa 2004].    
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3.2.1 Acylation: In quiescent cells, eNOS is targeted to invaginations of the plasmalemma called 
caveolae, which are membrane microdomains defined by the presence of the scaffolding protein 
caveolin.  The caveolae are enriched in cholesterol and sphingolipids, and sequester diverse 
receptors and signaling proteins from a variety of signal transduction pathways, including G-
protein coupled receptors, G proteins, growth factor receptors, calcium regulatory proteins, as 
well as eNOS. The targeting of eNOS may permit the enzyme to receive signals from these 
upstream signaling pathways and facilitate communication with downstream activators.   The 
targeting of eNOS to caveolae is dependent on the irreversible co-translational myristoylation of 
its N-terminal glycine, followed by the dynamically regulated post-translational palmitoylation 
of the Cys15 and Cys26 residues.  Myristoylation and palmitoylation comprise three acyl 
anchors that attach eNOS to the membrane. N-myristoylation of eNOS is catalyzed by an N-
myristoyltransferase that recognizes a specific N-terminal consensus sequence.  By contrast, no 
consensus sequence has been identified for thiopalmitoylation, and a family of 
palmitoyltransferases with varying substrate specificities and patterns of expression contribute to 
the process.   In particular, palmitoyltransferase protein DHHC-21 may be implicated in the 
palmitoylation of eNOS. DHHC-21 co-localizes with the enzyme, but its specificity for eNOS 
palmitoylation has not been established.  Depalmitoylation of eNOS is catalyzed by acyl protein 
thioesterase-1 (APT-1), an enzyme that also depalmitoylates the G protein Gαs.  By contrast to 
the irreversible fatty acyl amide that links myristate to eNOS, the thiopalmitoyl bonds linking 
palmitate to eNOS are labile. Prolonged agonist stimulation of eNOS leads to depalmitoylation 
and intracellular translocation, possible serving as a mechanism for modulating eNOS signaling 
responses [Dudzinski and Michel 2007; Feron et al. 2006; Shaul 2002].  
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3.2.2 Intracellular Calcium:  Calmodulin Binding: The activation of eNOS is critically 
dependent on the binding of the ubiquitous intracellular calcium regulatory protein calmodulin.  
Calmodulin binding to eNOS facilitates transfer of electrons between the enzyme’s reductase and 
oxygenase domains, and simultaneously disrupts the inhibitory caveolin-eNOS interaction. A 
diverse group of agonists, including bradykinin, sphingosine 1-phosphate, and acetylcholine, 
activate a G protein-dependent signaling pathway that ultimately releases intracellular calcium 
stores.   Receptor-dependent activation of phospholipase C (PLC) cleaves the cell membrane 
component phosphatidylinositol 4, 5-triphosphate into diacylglycerol (an activator of protein 
kinase C) and inositol 1, 4, 5-triphosphate (IP3), which binds to IP3 receptors, regulators of the 
intracellular calcium concentration densily located in caveolae [Fleming and Busse 2003].  
3.2.3 Phosphorylation: protein kinases and phosphoprotein phosphatases: Phosphorylation and 
dephosphorylation networks complement acylation and calmodulin as major post-translational 
regulatory influences on eNOS activity [Sessa 2004; Dudzinski 2007].  Key serine and threonine 
residues in eNOS constitute regulatory loci:  phosphorylations at Ser 1177 (primary sequence 
numbering corresponding to human eNOS), Ser 635, and Ser 617 promote increases in enzyme 
activity, while phosphorylation at Thr 495 and Ser 116 are inhibitory.  Ser 1177 phosphorylation 
is catalyzed by numerous kinases, including kinase Akt (protein kinase B) as well as the cyclic 
AMP-dependent protein kinase (PKA), AMP-activated protein kinase (AMPK), PKG, and 
calcium/calmodulin-dependent protein kinase II (CaM kinase II).   The relative contributions of 
these different kinase pathways are not completely understood, but it is already obvious that 
different extracellular stimuli activate distinct kinase pathways leading to eNOS 
phosphorylation.   For example, PKA appears to be the principal kinase that phosphorylates 
eNOS at ser1177 in response to hemodynamic shear stress [Balligand et al. 2009], while S1P- 
and VEGF-dependent phosphorylation of this same serine residue involves kinase Akt.   An 
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additional level of complexity is revealed by the fact that beta3 adrenergic receptor signaling to 
eNOS in endothelial cells involves both PKA and Akt.  Another critical kinase is the AMP-
activated protein kinase, which has broad effects on endothelial metabolism and signaling 
[Fisslthaler and Fleming 2009].  AMPK can catalyze eNOS phosphorylation at ser1177, yet 
AMPK is also the principal kinase that phosphorylates eNOS at ser635[Chen et al. 2009].  
Indeed, AMPK plays a key role in multiple phosphorylation pathways involving eNOS 
modulation, and AMPK is in turn regulated by upstream serine/threonine kinases including the 
calcium-calmodulin kinase kinase-beta [Levine et al. 2007].   In addition, tyrosine 
phosphorylation of eNOS Tyr 83 mediated by v-Src has been identified as another candidate 
eNOS post-translational modification [Fulton et al. 2005].  However, the extracellular signals 
that modulate phosphorylation at this site remain incompletely understood. In particular, it is 
unclear whether Tyr 83 phosphorylation is responsible principally for activating eNOS catalytic 
activity, or whether this site modulates signaling by serving as a binding site for proteins with 
Src homology (SH3) domains. 
The relative contribution of protein phosphatases versus phosphoprotein kinases in eNOS 
regulation also remains uncertain.  Thus, depending on the specific phosphorylation site, 
dephosphorylation of eNOS can either activate or inhibit enzyme activity.  Several phosphatases, 
including serine-threonine protein phosphatase 1 (PP1), serine-threonine protein phosphatase 2A 
(PP2A), and calcineurin participate in eNOS regulation.  A pathway involving the phosphatase 
calcineurin leads to dephosphorylation of Ser 116 and to the activation of eNOS.  The 
immunosuppressive drug cyclosporine inhibits calcineurin, preventing VEGF-induced Ser 116 
dephosphorylation and thus offering a potential mechanism to explain the mechanism of 
cyclosporine-induced hypertension. [Fleming and Busse 2003, Dudzinksi et al 2006, Govers and 
Rabelink 2001] 
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3.2.4 S-Nitrosylation: Reversible S-nitrosylation provides an additional level of in vivo dynamic 
receptor-mediated post-translational control of the eNOS enzyme in endothelial cells. Indeed, 
eNOS appears to be the source of the NO required for its own S-nitrosylation, implying a spatial 
mechanism of specificity in nitrosylation of Cys 94 and Cys 99 given the approximately thirty 
cysteine residues in eNOS. S-nitrosylation of eNOS leads to enzyme inhibition, whereas 
denitrosylation is associated with an increased enzyme activity.  Treatment of cultured 
endothelial cells or intact blood vessels with eNOS agonists promotes rapid and reversible de-
nitrosylation of eNOS, temporally associated with enzyme activation.  The return to basal eNOS 
enzyme activity following agonist treatment is associated with the re-nitrosylation of eNOS.  
These findings imply some component of temporal selectivity in nitrosylation reactions given 
that eNOS is denitrosylated during the period of maximal NO production.  Like phosphorylation 
and acylation, subcellular localization affects eNOS S-nitrosylation and may help generate the 
apparent temporal selectivity.  Membrane targeting is required for S-nitrosylation, as shown by 
experiments in which eNOS S-nitrosylation is virtually abolished in the myristoylation-deficient 
mutant (Myr¯ ) recombinant eNOS [Erwin et al. 2006] as compared to the hyper-nitrosylation of 
the membrane-tethered fusion protein CD8-Myr¯ eNOS.  The subcellular dependence of 
nitrosylation may reflect distinct chemical environments that favor or disfavor nitrosylation 
(Lamas et al. 2001).   
 
 
3.3  Protein-protein interactions in eNOS regulation 
3.3.1 Caveolin: Caveolins are ~22kDa intrinsic membrane proteins [see reviews in Gratton et al. 
2004, Shaul 2003, Shaul 2002]. Caveolin-1 and caveolin-2 are ubiquitously expressed and 
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abundant in endothelial cells, while caveolin-3 is a muscle-specific isoform expressed in 
cardiomyocytes and skeletal muscle.  Robust protein-protein interactions lead to the binding of 
caveolar-localized eNOS with caveolin-1, although this protein-protein interaction is apparently 
not necessary for the localization of eNOS to caveolae [Gonzalez et al. 2004].  Caveolin tonically 
inhibits eNOS in quiescent cells both by impeding the signaling of caveolae-targeted receptors 
that transduce eNOS-stimulatory signals as well as by inhibiting calmodulin binding to eNOS. 
Diseases in which caveolins have been implicated include atherosclerosis, hypertension, 
cardiomyopathy, diabetes, and oncogenesis.  
3.3.2 Heat Shock Proteins: Heat shock protein 90 (hsp90), a chaperone involved in protein 
trafficking and folding, modulates agonist-dependent eNOS activation [Sessa 2004]. Hsp90 
binding stimulates eNOS activity, and also affects eNOS specific activity by binding to kinase 
Akt. This interaction may be dynamically regulated by hsp90 S-nitrosylation (Martinez-Ruiz et 
al, PNAS 102: 8525, 2005) and by statins. Among other effects on eNOS signaling pathways, 
statins appear to stimulate eNOS phosphorylation by Akt; one Akt-dependent effect of statins 
involves tyrosine phosphorylation of hsp90, which in turn facilitates hsp90 binding and activation of Akt.    
 
3.3.3 Actin Cytoskeleton: Dynamic structural changes in the actin cytoskeleton impact on eNOS 
via links to caveolar membrane domains and caveolar membrane associated proteins [see 
reviews in Su et al. 2003; Skidgel 2002). For example, shear stress may transduce its effect on 
eNOS via actin-based cellular architecture.  Furthermore, caveolin and caveolae may use the 
actin network to reversibly translocate between plasmalemma and the intracellular vesicles.  
Connections between plasmalemmal caveolae and the cytoskeleton have been identified in many 
cellular systems, and may play a key role in the involvement of the cytoskeleton-associated 
GTPase Rac1 in eNOS activation.  Modulation of Rac1 and other members of the Rho GTPase 
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family by statins may represent another important pathway for the control of eNOS signaling 
pathways by these therapeutic agents [Du et al. 2001].  
3.3.4 NOSIP and NOSTRIN: Two eNOS-associated proteins identified using yeast two-hybrid 
screening include the eNOS Interacting Protein NOSIP [Schilling et al. 2006], and the eNOS 
TRafficking INducer protein NOSTRIN [Icking et al. 2005; see review in Dudzinski 2007].  
NOSIP is a 34kDa protein that binds the carboxy-terminal of the eNOS oxygenase domain and 
assists in the translocation of eNOS from the plasma membrane caveolae to intracellular 
membranes. Association of eNOS and NOSIP is inhibited by caveolin-1.   NOSTRIN is robustly 
expressed in the endothelium.  Overexpression of NOSTRIN can promote the translocation of 
eNOS from the plasma membrane to intracellular vesicles, with a concomitant reduction in 
eNOS enzyme activity. NOSTRIN-dependent shuttling of eNOS is caveolin-dependent and likely 
reflects specialized endocytosis of caveolar endosomes involving the actin cytoskeleton.  
 
4. Modulation of the protective role of Nitric Oxide 
4.1. Up-regulation 
4.1.1 Shear Stress: Both acute and chronic increases in flow, and the resulting increasing force of 
shearing (shear stress) of the blood on the endothelial cells, augment the expression and the 
activity of eNOS, and thus the release of EDRF/NO (Figure 2) [Rubanyi et al., 1986; Miller & 
Vanhoutte, 1988; Davies, 1995; Busse & Fleming, 2003; Balligand 2009]. The immediate effect 
of an increase in shear stress on the release of NO explains flow-mediated dilatation (FMD), a 
phenomenon commonly used to estimate endothelial function in people.  In the porcine and 
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human coronary circulation, flow-dependent vasodilatation involves the local production of 
bradykinin that stimulates the release of NO through a Gq-dependent mechanism (Figure 2) [see 
Vanhoutte et al., 2009]. The chronic effect of shear stress is due to an up-regulation of eNOS and 
a greater activation (phosphorylation) of the enzyme, leading to a larger release of NO for each 
given stimulation, explaining the beneficial effects of regular exercise on endothelial function [ 
see Vanhoutte et al., 2009].  
4.1.2 Estrogens and Gender: The reintroduction of physiological levels of estrogens in 
ovariectomized animals augments endothelium-dependent relaxations [see Vanhoutte et al., 
2009]. The potentiating effect of estrogens on endothelium-dependent relaxations involves both 
genomic (Figure 2) and non-genomic effects [see Miller & Duckles, 2008; see Vanhoutte et al., 
2009]. Phytoestrogens and selective estrogen receptor modulators (SERMs) also potentiate 
endothelium-dependent relaxations/vasodilatations [see Vanhoutte et al., 2009]. In coronary 
arteries, the potentiating effect of chronic treatment with estrogens is seen only with stimuli that 
activate Gi-coupled receptors on the endothelial cells and is counteracted by the chronic 
administration of progesterone [Miller & Vanhoutte, 1991]. It is likely that this potentiating 
effect of estrogens on NO release, presumably resulting from lower oxidative stress, helps to 
explain why endothelium-dependent relaxations are more pronounced in arteries from female 
than male animals and why pre-menopausal women are protected against coronary disease. The 
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opposing effects of progesterone helps to explain why hormone replacement therapy has not 
always had the expected beneficial cardiovascular effects [see Vanhoutte et al., 2009].  
4.1.3 Sphingolipids and Lysophospholipids:  A class of serum-borne lipid mediators including 
sphingosine 1-phosphate (S1P) and lyosphosphatidic acid activate endothelial G protein-coupled 
S1P receptors (formerly called EDG receptors) play key roles in vascular regulation [Hla 2001] 
stimulate AMP-activated protein kinase (AMPK) the small GTP binding protein Rac1, a critical 
determinant of the activity of eNOS.  
4.1.4 Diet: The chronic intake of ω3-unsaturated fatty acids potentiates endothelium-dependent 
relaxations and has antiatherogenic properties. The same holds true for the intake of flavonoids 
and other polyphenols of vegetal origin [see Vanhoutte et al., 2009].  
4.2. Down-regulation: 
 4.2.1 Oxygen-derived free radicals: Several enzymes in the endothelial cells can produce 
superoxide anions. They include NADPH oxidase, xanthine oxidase, cyclooxygenase and eNOS 
itself, when it is uncoupled by lack of substrate (L-arginine) or shortage of the essential co-factor 
tetrahydrobiopterin [see Kojda & Harrison 1999; Fleming et al., 2005]. Superoxide anions can be 
dismutated by superoxide dismutase (SOD) to hydrogen peroxide (H2O2) which can act as an 
EDHF and contribute to endothelium-dependent relaxations [see Feletou & Vanhoutte, 2006a, 
2009], or been broken down by catalase. However, superoxide anions also scavenge NO avidly 
with the resulting formation of peroxynitrite which reduces the bioavailability of NO [see Kojda 
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& Harrison, 1999; Rida, 2004]. Hence, increases in oxidative stress lead to reduced endothelium-
dependent relaxations, and antioxidants acutely improve such responses in vitro and in vivo both 
in animals and humans. However, chronic treatment with antioxidants usually fails to improve 
endothelial function in people [see Vanhoutte et al., 2009]. 
4.2.2 Aging: Both in animals and in humans, increasing age reduces the ability of the 
endothelium to elicit endothelium-dependent vasodilatations in vitro and in vivo [see Vanhoutte 
et al., 2009]. This has been attributed to increased activity of arginase [competing with eNOS for 
the common substrate arginine], augmented production of superoxide anions reducing NO 
bioavailability, reduced expression/presence and/or activity of eNOSand ultimately NO lesser 
release of [see Vanhoutte et al., 2009].  
4.3.3 Hypercholesterolemia: Both in animals and in humans, high fat diets reduce endothelium-
dependent relaxations/dilatations and the normalization of the cholesterol level with treatment 
restores endothelial function. The effect of hypercholesterolemia is due to the combination of 
increased oxidative stress leading to a reduced bioavailability of NO, impairment of the turnover 
rate of eNOS and augmented levels of circulating asymmetric dimethyl arginine (ADMA, an 
endogenous inhibitor of eNOS) [see Vanhoutte et al., 2009].  In addition, lipoproteins appear to 
reduce eNOS targeting to plasmalemmal caveolae as well the interactions of the enzyme with 
caveolin and other regulatory proteins that influence its activity [Feron and Balligand, 2006]. 
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4.3. Cardiovascular disease 
4.3.1 Hypertension: Endothelium-dependent relaxations are reduced in i arteries harvested from 
hypertensive animals, and responses to endothelium-dependent vasodilators are decreased in 
hypertensive humans.  This blunting, which can be corrected by an appropriate treatment 
probably reflects the premature aging of the vasculature exposed chronically to the increased 
arterial blood pressure [see Vanhoutte et al., 2009]. In the spontaneously hypertensive rats and in 
the essential hypertensive human the reduction of endothelium-dependent 
relaxations/vasodilatations is caused mainly by the concomitant release of endothelium-derived 
vasoconstrictor prostanoids (endothelium-derived contracting factors; EDCF) rather than to a 
reduced release of NO [see Vanhoutte et al., 2005, 2009; Vanhoutte and Tang, 2009].  
4.3.2 Diabetes: Insulin resistance and diabetes cause an impairment of arterial endothelium-
dependent relaxations in animals and humans, presumably due to the chronic exposure to 
hyperglycemia [see De Vriese et al., 2000; Vanhoutte et al., 2009]. The endothelial dysfunction 
of diabetes has been attributed to a relative deficiency of reduced tetrahydrobiopterin, associated 
with inceased eNOS “uncoupling” and ROS production [Katucic 2009; Fleming and Busse 2003; 
Katusic 2001; Lubos et al. 2008; Moens and Kass 2006; Thomas et al. 2008; Wolin 2009], 
increased activity of arginase competing with eNOS for the common substrate, arginine, elevated 
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levels of the endogenous inhibitor ADMA, augmented production of superoxide anions and thus 
increased formation of peroxynitrite, and quenching of NO by advanced glycosylation products  
[see Vanhoutte, 2008; Vanhoutte et al., 2009].   
4.3.3 Coronary Disease: Individuals at increased risk of coronary heart disease exhibit impaired 
dilatations in response to endothelium-dependent vasodilators both in the peripheral and 
coronary circulations. Both in animals and humans, the presence of such endothelial dysfunction 
predicts the severity of the outcome, in particular the occurrence of myocardial infarction [see 
Vanhoutte et al., 2009]. 
5. Regenerated endothelium 
After maturation, endothelial cells remain quiescent for years before aging and apoptotic 
programming initiate their turnover, although the latter is accelerated by cardiovascular risk 
factors (obesity, smoking, hypertension and diabetes). When apoptotic endothelialcells die, they 
are replaced rapidly by regenerated endothelial cells [see Vanhoutte et al., 2009]. Regenerated 
endothelial cells are dysfunctional (Figure 4). Thus, coronary arteries covered with regenerated 
endothelium exhibited a marked blunting of the endothelium-dependent relaxations to agonists 
using the Gi-protein signaling cascade (aggregating platelets, serotonin or thrombin) and the 
remaining response is no longer inhibited by pertussis toxin. By contrast, relaxations evoked by 
ADP and bradykinin, which both depend on the Gq-signaling cascade are normal, illustrating the 
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ability of the regenerated endothelial cells to generate NO. These observations imply a selective 
dysfunction of the Gi-dependent responses in regenerated endothelial cells. This selective 
dysfunction is reduced by the chronic intake of ω3-unsaturated fatty acid, and exacerbated by a 
high fat diet which results in the occurrence of typical atherosclerotic lesions only in the part of 
the coronary artery covered with regenerated endothelium [see Vanhoutte et al., 2009]. Thus, the 
selective dysfunction of regenerated endothelial cells appears to be an initial step allowing the 
atherosclerotic process. 
Primary cultures derived from regenerated endothelial cells are characterized by accelerated 
senescence, reduced expression and activity of eNOS, greater production of oxygen-derived free 
radicals by the endothelial NADPH oxidase, greater uptake of modified low-density lipoprotein 
cholesterol (LDL) and larger generation of oxidized LDL (oxyLDL). By contrast, the presence of 
Gi-proteins is comparable to that observed in primary cultures derived from native endothelium. 
The genomic changes observed in cultures of regenerated endothelial cells are in line with those 
phenotypic and functional changes.  These experimental findings prompt the conclusion that the 
augmented presence of oxyLDL is responsible for the selective loss in Gi-protein mediated 
responses in regenerated endothelial cells and thus of their inability to respond to serotonin and 
thrombin [Figure 2] [see Vanhoutte et al., 2009]. Obviously, this is not the only deleterious 
effect of oxygen-derived free radicals and oxyLDL which play a central role in the 
atherosclerotic process (Figure 5) [Thomas et al. 2008; Stocker & Keany, 2004]. Other factors 
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include inhibition of  the expression, reduced activation (dephosphorylation) and uncoupling of 
eNOS and an enhanced activity of arginase, which competes with NO for the common substrate 
arginine (Figure 6) [Katusic, 2007; Vanhoutte 2008; see Vanhoutte et al., 2009]. In addition, a 
greater production of superoxide anions will reduce the bioavailability of NO and increase the 
levels of peroxynitrite [Kojda & Harrison 1999; Fleming et al., 2005; Cai 2005; Schroder and 
Eaton 2008; Thomas et al. 2008; Wolin 2009]. Endogenous mediators, other than the increased 
presence of oxyLDL, may accelerate or contribute to the atherosclerotic process. This may be in 
particular the case for the emergence of fatty acid-binding proteins in regenerated endothelial 
cells [Lee et al., 2007; Furuhashi & Hotamisligil, 2008]. Whatever the cause of the dysfunction, 
regenerated endothelial cells cannot produce enough NO in response to platelets and thrombin, 
and this NO deficiency permits the inflammatory reaction leading to atherosclerosis [Aikawa & 
Libby, 2004].  
 
6. Conclusions: 
In native, healthy endothelial cells a number of stimuli (e.g. serotonin from aggregating platelets, 
sphingosine 1-phosphate, and thrombin) activate eNOS causing the release of NO, which relaxes 
the vascular smooth muscle that surrounds them. NO, in synergy with prostacyclin, further 
inhibits platelet aggregation. It also reduces the endothelial expression of adhesion molecules 
and thus the adhesion and penetration of leukocytes (macrophages). The endothelial mediator 
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also prevents the proliferation of vascular smooth muscle cells and limits the formation of oxy 
LDL. Aging and certain lifestyle factors (e.g. lack of exercise, Western diet, smoking), or certain 
diseases (e.g. diabetes and hypertension) result in a lesser release of NO and an acceleration of 
the turnover of the apoptotic process in the endothelium. The apoptotic endothelial cells are 
replaced by regenerated ones. However, such regenerated cells are dysfunctional, senescent, and 
incapable of producing the required amounts of NO, which facilitates the inflammatory response 
leading to the formation of atherosclerotic plaques.  
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Figure Legends:  
Figure 1. Some of the neurohumoral mediators that cause the release of endothelium-
derived relaxing factors (EDRF) through activation of specific endothelial receptors (circles).  E, 
epinephrine; AA, arachidonic acid; Ach, acetylcholine; ADP, adenosine diphosphate; α = alpha 
adrenergic receptor; AVP, arginine vasopressin; B, kinin receptor; ET, endothelin, endothelin-
receptor; H, histaminergic receptor; 5-HT, serotonin (5-hydroxytryptamine), serotoninergic 
receptor; M, muscarinic receptor; NE, norepinephrine; P, purinergic receptor; T, thrombin 
receptor; VEGF, vascular endothelial growth factorVP, vasopressin receptor [From Vanhoutte et 
al., 2009. By permission]. 
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Figure 2. Schematic of possible mechanisms by which production of nitric oxide is 
regulated in endothelial cells.  Nitric oxide is produced through enzymatic conversion of L-
arginine by nitric oxide synthase (endothelial or type III, eNOS).  The transcription of this 
enzyme is regulated genomically by hormones and growth factors.  Stability of eNOS mRNA is 
modulated by statins and hormones.  eNOS enzyme activity requires calcium, calmodulin, 
nicotinamide adenine dinucleotide phosphate (NADPH), and 5, 6, 7, 8-tetra-hydrobiopterine 
(BH4).  Enzyme activity is regulated by complexing to these proteins in microdomains of the 
endothelial cell.  Association with this complex of heat shock protein 90 (HSP 90) increases 
enzyme activity. Stimulation of specific receptors on the endothelial surface (R) complexed with 
guanine nucleotide regulatory proteins, which are sensitive to pertussis toxin (Gi) or insensitive 
to pertussis toxin (Gq), activate intracellular pathways that modulate eNOS activity 
posttranslationally through heat shock protein 90 or AKT-phosphorylation.  Association of 
eNOS with caveolin-1 or glycosylation of the enzyme reduces activity.  A metabolite of L-
arginine, asymmetric dimethyl arginine (ADMA) decreases production of the nitric oxide 
through competitive binding to eNOS.  Thus, this endogenous amine may be a risk factor for the 
development of cardiovascular disease.  +, indicates stimulation; -, indicates inhibition; ?, 
indicates those pathways in which the regulation is unknown [From Vanhoutte et al., 2009. By 
permission].Figure 3. Postulated G-protein  mediated signal transduction processes in a normal, 
native endothelial cell.  Activation of the cell causes the release of nitric oxide (NO), which has 
important protective effects in the vascular wall.  Abbreviations: 5-HT, serotonin receptor; B, 
bradykinin receptor; P, purinoceptor; G, coupling proteins [From Vanhoutte et al., 2009. By 
permission]. 
Figure 4. Effects of oxidized low-density lipoproteins (OXLDL) in a regenerated 
endothelial cell, resulting in the reduced release of nitric oxide (NO).  Abbreviations: 5-HT, 
serotonin receptor; B, bradykinin receptor; P, purinoceptor; G, coupling proteins [From 
Vanhoutte et al., 2009. By permission].   
Figure 5. Mechanisms of oxLDL-induced impairment of endothelial NO production.  The 
NO synthase (NOS) uses L-arginine to generate NO.  NO production could be attenuated in the 
presence of oxLDL by interfering with the supply of L-arginine to the enzyme through 
endogenous competitive inhibitors such as asymmetrical dimethyl-L-arginine (ADMA) as well 
as degradation of arginine through arginase.  NOS expression and specific activity are decreased 
by oxLDL through RhoA and PKC.  NO bioavailability is reduced by an oxLDL-mediated 
activation of the NADPH oxidase, which leads to superoxide anion (O2-) formation.  This 
process facilitates the generation of peroxynitrite (ONOO-), which subsequently oxidizes 
tetrahydrobiopterin (BH4) of NOS, leading to NOS uncoupling [Berka et al., 2004].  Uncoupled 
NOS itself produces O2-, further promoting the process of BH4 oxidation. [From Vanhoutte et al., 
2009. By permission].   
Figure 6.   Overview of principal eNOS post-translational modifications.  eNOS undergoes dual 
acylation: co-translational N-myristoylation at glycine 2 and reversible post-translational 
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thiopalmitoylation at cysteine 15 and cysteine 26.  [The numbering scheme used here reflects the 
amino acid sequence of bovine eNOS, which has been extensively characterized.]  eNOS-derived 
NO promotes S-nitrosylation at cysteines 96 and 101, leading to enzyme inhibition (signified by 
the red arrow).  Phosphorylation at serine 116 and threonine 497 leads to enzyme inhibition, and 
phosphorylations at serines 617, 635 and 1179 and at tyrosine 83 generally increase enzyme 
activity.  Other eNOS post-translational modification sites have been more recently described, 
and are being actively investigated.  References are in the text. 
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